FDA QMSR Is Here: What ISO 13485 Alignment Means for Medical Device Quality Systems

For medical device and IVD quality, regulatory, and operations leaders, this briefing explains the most important Q1 2026 regulatory changes and what to prioritize now, from FDA QMSR and ISO 13485 alignment to EUDAMED expansion and proposed EU MDR/IVDR reforms. In this executive briefing, Berkin Güler (Senior Manager, Quality Management Consulting at NSF) reviews the most significant medical device and IVD regulatory developments announced in Q1 2026 and translates them into practical priorities for regulated organizations. A major theme is FDA quality system modernization: the transition from the legacy QSR approach to the Quality Management System Regulation (QMSR) and what it changes for inspection readiness. With FDA’s inspection approach updated and expectations moving closer to international audit practice, teams should be prepared for documentation and procedures that align to ISO 13485:2016, including updated terminology and broader access to records such as management review outputs and internal audit reports. We then break down what “harmonization” really means in practice. FDA’s incorporation of ISO 13485 by reference fundamentally shifts how global manufacturers can design and operate an integrated quality management system, reducing the friction of parallel frameworks while still requiring attention to U.S.-specific requirements. Key operational impacts include a more integrated “medical device file” concept (rather than separate DHF/DMR/DHR structures), stronger emphasis on documented competency and training effectiveness, and explicit risk-based thinking across processes, including supplier controls and risk management integration aligned to ISO 14971 expectations. The session also covers several high-impact developments affecting compliance strategy, digital transformation, and commercialization planning: EU breakthrough device guidance (MDCG) and a pilot program designed to provide expedited pathways and more structured dialogue with notified bodies for qualifying innovations. [transcript...updates Q1 | Word] EUDAMED/UDI obligations expanding in 2026, with mandatory modules (actor registration, UDI/device registration, notified body certificates, and market surveillance data) increasing transparency and making data gaps more immediately actionable for authorities. PFAS regulatory clarity and the emerging complexity of state-level requirements in the U.S., reinforcing the need for distribution-aware compliance assessments, exemption verification, and defensible documentation of intentional PFAS use where relevant. MDSAP Audit Approach version 10 updates, including deeper alignment to FDA QMSR and ISO 13485 as the backbone, with jurisdiction-specific add-ons assessed within a more integrated audit model. FDA’s revised 2026 Clinical Decision Support (CDS) guidance, clarifying boundaries for non-device CDS, expectations around transparency, and where functions like image analysis are likely to remain within FDA oversight. Finally, we assess the European Commission’s proposal to amend the EU MDR and EU IVDR (announced December 2025) and what it may mean for clinical evidence, equivalence, administrative burden reduction, and predictability. The discussion highlights potential changes to clinical investigation expectations for certain device classes, possible shifts in how equivalence to third-party devices can be justified, and a proposed requirement to substantiate single-use claims using design and risk management rationale. If you lead quality systems, regulatory affairs, clinical operations, manufacturing, or supply chain governance for medical devices, IVD, combination products, or digital health, this briefing provides a practical lens on readiness actions that protect patient safety, support compliant commercialization, and reduce inspection risk. Learn more about NSF’s medical device services here: https://www.nsf.org/gb/en/life-scienc... 00:00 Introduction and what this briefing covers 01:10 Q1 2026 regulatory update overview 02:05 FDA QMSR modernization and inspection approach changes 05:10 EU breakthrough device guidance and pilot program 07:30 EUDAMED expansion: mandatory modules and implications 09:40 PFAS: FDA position vs. state-level requirements 12:00 MDSAP Audit Approach v10: what changes for audits 14:40 FDA 2026 CDS guidance: non-device vs device boundaries 17:10 Why FDA–ISO 13485 harmonization matters 19:10 Key QMSR operational changes: MDF, competency, risk-based thinking 24:10 Supplier controls and risk management integration (ISO 14971 linkage) 27:00 Practical implementation roadmap for organizations 30:10 Proposed EU MDR/IVDR amendments: goals and timelines 34:20 Clinical evidence and equivalence: what may change 38:30 Single-use justification: evidence and risk management expectations 41:30 What to do now: stay ready, stay compliant 43:10 Close and NSF resources